Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

SML2283

Sigma-Aldrich

Lenalidomide

≥98% (HPLC), powder, cereblon binder

Synonym(s):

Lenalidomide, 1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole, 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidin-2,6-dione, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CC 5013, CC-5013

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H13N3O3
CAS Number:
191732-72-6
Molecular Weight:
259.26
MDL number:
MFCD07772307
UNSPSC Code:
12352200
NACRES:
NA.77
Pricing and availability is not currently available.

Product Name

Lenalidomide, ≥98% (HPLC)

ligand

lenalidomide

assay

≥98% (HPLC)

form

powder

reaction suitability

reagent type: ligand

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C1N(C2CCC(NC2=O)=O)CC3=C1C=CC=C3N

InChI

1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
901558P0018T144
Lenalidomide ≥98% (HPLC)

SML2283

Lenalidomide

Lenalidomide ≥95%

901558

Lenalidomide

Pomalidomide ≥98% (HPLC)

P0018

Pomalidomide

(±)-Thalidomide ≥98%, powder

T144

(±)-Thalidomide

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥95%

assay

≥98% (HPLC)

assay

≥98%

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

solubility

DMSO: 2 mg/mL, clear

solubility

-

solubility

DMSO: ≥14 mg/mL

solubility

DMSO: 20 mg/mL, clear

color

white to beige

color

-

color

yellow

color

white

ligand

lenalidomide

ligand

lenalidomide

ligand

pomalidomide

ligand

thalidomide

Biochem/physiol Actions

Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent that is approved drug for treatment of multiple myeloma. Apparently Lenalidomide is a ligand of ubiquitin E3 ligase cereblon that induces the enzyme to degrade the Ikaros transcription factors IKAROS family zinc finger 1 (IKZF1) and IKZF3. Lenalidomide possess pleiotropic antitumor effects.[1] It is used in the treatment of 5q-deletion associated myelodysplastic syndrome (del(5q)-MDS).[2]

related product

Product No.
Description
Pricing

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Repr. 1B - STOT RE 2

target_organs

Blood

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

    If you need assistance, please contact Customer Support

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Yuan Xiao Zhu et al.
    Blood, 118(18), 4771-4779 (2011-08-24)
    The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of
    Hila Shaim et al.
    Frontiers in immunology, 8, 1773-1773 (2018-01-31)
    Chronic lymphocytic leukemia (CLL) cells possess regulatory functions comparable to those of normal B10 cells, a regulatory B cell subset that suppresses effector T-cell function through STAT3-mediated IL-10 production. However, the mechanisms governing IL-10 production by CLL cells are not
    Georg Petzold et al.
    Nature, 532(7597), 127-130 (2016-02-26)
    Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous
    Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
    Donovan KA, et al.
    eLife, 7, e38430-e38430 (2018)
    Antoine Domenger et al.
    Frontiers in oncology, 13, 1110916-1110916 (2023-02-14)
    Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are generally effective in newly diagnosed patients
    View All Related Papers

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service